Marijuana may hold the hot seat for a constantly fueled debate, but there is a unanimous agreement on the miraculous use of medical marijuana in curing ailments and fatal diseases. In some recorded cases, it has been known to reverse the effects entirely.
The Australian and New Zealand Clinical Trial Registry has registered clinical trials for cannabidiol (CBD)-based mouthwash and toothpaste to treat gingivitis and periodontitis (gum disease). CBD oil has already formed the basis of studies for cancer, seizures and more with evident case histories. This endeavor increases the movement of CBD and increases its scope in healthcare research. Commercialization of CBD continues to be the center of controversy. These trials will test the efficacy and clinical safety of the formulation.
The trail studies 40 test subjects suffering from gingivitis and gum disease, who will be using the mouthwash and toothpaste over a period of 30 days. Their progress will be closely monitored.
The manufacturer is of this formulation is US-based AXIM Biotechnologies. Australia’s special access scheme which allows access to therapeutic goods that are not listed under the Australian Register of Therapeutic Goods (ARTG) nor are they exempt from being in the ARTG, will be a vehicle to boost sales of the formulation if found effective.
Inflammations and gum related diseases are not uncommon in Australia, especially the demographic over 55 years, where they are found more widespread.
The trails will be jointly funded by Impression Healthcare, Swinburne University of Technology and Australia’s largest medicinal cannabis product distributor Cannvalate.